Latest Ratios: P/E Ratio -0.5x · EV/EBITDA 286.8x · ROE -14.9%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $8M | $6M | $4M | $13M | $39M | $83M | $70M | $56M | $116M | $93M |
| Enterprise Value | $10M | $9M | $6M | $1M | $13M | $31M | $77M | $71M | $55M | $116M | $91M |
| P/E Ratio → | -0.54 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | 207.82 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.17 | 0.25 | 0.11 | 1.18 | 4.82 | — | — | 15.15 | 12.53 | 42.45 | 28.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 242.67 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 286.83 | — | 192.06 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -19540.0% | -19540.0% | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | -18078.3% | -18078.3% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.9% | -14.9% | -58.8% | -497.9% | -533.5% | — | -3305.9% | -333.9% | -375.6% | -373.3% | -454.1% |
| ROA | -9.8% | -9.8% | -39.1% | -256.4% | -169.8% | -473.7% | -299.4% | -185.4% | -193.1% | -166.8% | -217.1% |
| ROIC | -11.9% | -11.9% | -0.0% | -793.6% | — | — | — | -0.2% | -0.3% | -0.4% | -0.3% |
| ROCE | -15.5% | -15.5% | -0.1% | -470.3% | -1036.7% | — | -2649.0% | -0.3% | -0.3% | -0.2% | -0.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.00 | 0.23 | 0.32 | — | — | 0.35 | 0.06 | 0.15 | 0.05 |
| Debt / EBITDA | — | — | 4.22 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.04 | -0.00 | -0.80 | -0.17 | — | — | 0.31 | -0.19 | -0.06 | -0.50 |
| Net Debt / EBITDA | — | — | -0.69 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -14.43 | -14.43 | — | -702.16 | -920.32 | -5209.31 | -4.59 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 3.03 | 1.58 | 1.37 | 0.77 | 0.51 | 0.80 | 1.60 | 0.79 | 1.27 |
| Quick Ratio | 0.17 | 0.17 | 3.03 | 1.58 | 1.37 | 0.77 | 0.51 | 0.80 | 1.60 | 0.79 | 1.27 |
| Cash Ratio | 0.06 | 0.06 | 0.01 | 1.18 | 0.55 | 0.67 | 0.39 | 0.04 | 0.37 | 0.23 | 0.76 |
| Asset Turnover | — | 0.00 | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 13180.45 | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | 4.5% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 4.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $3M | $336342 | $35912 | $2125 | $677 | $534 | $368 | $253 | $155 |
Imminent liquidity and dilution
According to recent market data, ENTO trades at a P/B ratio of 0.17, which, when compared to the broader biotechnology sector, suggests that the market assigns minimal value to the company's intangible assets and is heavily discounting the potential success of its clinical-stage pipeline.
The extremely low P/B multiple indicates that investors are pricing the company as a distressed entity rather than a going concern. This valuation suggests that the market is skeptical of the company's ability to convert its acquired intellectual property into a commercialized product without further significant equity dilution.
As reported in financial statements, ENTO's ROIC has consistently remained in negative territory, reaching -5.9% in 2025Q4, which demonstrates that the company is currently unable to generate positive returns on the capital deployed into its clinical development programs.
The persistent negative ROIC trend reflects the high cost of R&D and clinical trial management relative to the company's lack of commercial revenue. This pattern suggests that capital is being consumed to sustain operations rather than compounding value, which warrants caution regarding the efficiency of current management's capital allocation.
Based on 2025Q4 filings, ENTO's current ratio has deteriorated to 0.17, a sharp decline from the 5.49 ratio observed in 2024Q2, signaling that the company's ability to meet its near-term financial obligations is severely constrained without immediate access to additional capital.
The collapse in the current ratio highlights an urgent liquidity risk that could force the company to seek dilutive financing or pursue strategic alternatives. Investors should monitor the cash runway closely, as the current liquidity position appears insufficient to support the capital-intensive requirements of Phase 3 clinical trials.
Analysts frequently misapply P/E and EV/EBITDA multiples to ENTO, which obscures the reality that these metrics are fundamentally irrelevant for a pre-commercial biotech firm that lacks recurring revenue and positive operating cash flow.
Using earnings-based multiples for ENTO is misleading because the company's net losses are driven by clinical development costs rather than operational inefficiency. A more appropriate analytical framework would focus on cash burn rates and the probability-weighted net present value of the latiglutenase pipeline assets.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENTO stock.
Entero Therapeutics, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Entero Therapeutics, Inc.'s current EV/EBITDA is 286.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Entero Therapeutics, Inc.'s return on equity (ROE) is -14.9%. The historical average is -285.9%.
Based on historical data, Entero Therapeutics, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Entero Therapeutics, Inc. has -19540.0% operating margin.